These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
4. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Ference BA; Cannon CP; Landmesser U; Lüscher TF; Catapano AL; Ray KK Eur Heart J; 2018 Jul; 39(27):2540-2545. PubMed ID: 29020411 [No Abstract] [Full Text] [Related]
5. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492 [TBL] [Abstract][Full Text] [Related]
6. New concepts in the management of dyslipidaemiaa. Gencer B; Rodondi N; Mach F Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791 [TBL] [Abstract][Full Text] [Related]
7. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Sisson EM; Pamulapati L; Bucheit JD; Kelly MS; Dixon DL Pharmacotherapy; 2018 Feb; 38(2):164-171. PubMed ID: 29266309 [No Abstract] [Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
9. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Auer J; Berent R Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380 [TBL] [Abstract][Full Text] [Related]
10. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. Gragnano F; Natale F; Concilio C; Fimiani F; Cesaro A; Sperlongano S; Crisci M; Limongelli G; Calabrò R; Russo M; Golia E; Calabrò P J Cardiovasc Med (Hagerstown); 2018 Feb; 19(2):75-77. PubMed ID: 29251697 [No Abstract] [Full Text] [Related]
11. [PCSK9 inhibitors: What place in the management of dyslipidemia?]. Sabouret P; Farnier M; Puymirat E Presse Med; 2019 Mar; 48(3 Pt 1):227-237. PubMed ID: 30853281 [TBL] [Abstract][Full Text] [Related]